State of New Jersey Common Pension Fund D held its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, Holdings Channel reports. The institutional investor owned 60,500 shares of the medical equipment provider’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Zimmer Biomet Holdings were worth $7,768,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ZBH. Rothschild Investment Corp IL increased its position in Zimmer Biomet Holdings by 1.1% in the first quarter. Rothschild Investment Corp IL now owns 62,484 shares of the medical equipment provider’s stock worth $7,630,000 after buying an additional 700 shares in the last quarter. Huntington National Bank increased its position in Zimmer Biomet Holdings by 20.2% in the first quarter. Huntington National Bank now owns 9,473 shares of the medical equipment provider’s stock worth $1,157,000 after buying an additional 1,593 shares in the last quarter. Oakbrook Investments LLC bought a new position in Zimmer Biomet Holdings during the first quarter worth $1,010,000. Ledyard National Bank increased its position in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 110 shares in the last quarter. Finally, DnB Asset Management AS increased its position in Zimmer Biomet Holdings by 16.2% in the first quarter. DnB Asset Management AS now owns 22,208 shares of the medical equipment provider’s stock worth $2,712,000 after buying an additional 3,100 shares in the last quarter. 83.62% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 111.70 on Friday. The company’s 50-day moving average is $124.93 and its 200 day moving average is $121.26. The stock has a market cap of $22.59 billion, a P/E ratio of 31.81 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is 27.59%.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/state-of-new-jersey-common-pension-fund-d-maintains-stake-in-zimmer-biomet-holdings-inc-zbh/1476802.html.

A number of equities analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. Stifel Nicolaus reaffirmed a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $136.90.

In other news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.